These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37741348)

  • 1. Galectin-3 contributes to acute cardiac dysfunction and toxicity by increasing oxidative stress and fibrosis in doxorubicin-treated mice.
    Seropian IM; Fontana Estevez FS; Villaverde A; Cacciagiú L; Bustos R; Touceda V; Penas F; Selser C; Morales C; Miksztowicz V; González GE
    Int J Cardiol; 2023 Dec; 393():131386. PubMed ID: 37741348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Doxorubicin Myocardial Injury: Inflammatory, Oxidative Stress, and Apoptotic Role of Galectin-3.
    Al-Salam S; Kandhan K; Sudhadevi M; Yasin J; Tariq S
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Galectin-3 inhibition attenuates doxorubicin-induced cardiac dysfunction by upregulating the expression of peroxiredoxin-4.
    Tian Y; Lv W; Lu C; Jiang Y; Yang X; Song M
    Can J Physiol Pharmacol; 2020 Oct; 98(10):700-707. PubMed ID: 32516552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulated galectin-3 is not a critical disease mediator of cardiomyopathy induced by β
    Nguyen MN; Su Y; Kiriazis H; Yang Y; Gao XM; McMullen JR; Dart AM; Du XJ
    Am J Physiol Heart Circ Physiol; 2018 Jun; 314(6):H1169-H1178. PubMed ID: 29424570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vivo Protective Effects of Diosgenin against Doxorubicin-Induced Cardiotoxicity.
    Chen CT; Wang ZH; Hsu CC; Lin HH; Chen JH
    Nutrients; 2015 Jun; 7(6):4938-54. PubMed ID: 26091236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy.
    van Almen GC; Swinnen M; Carai P; Verhesen W; Cleutjens JP; D'hooge J; Verheyen FK; Pinto YM; Schroen B; Carmeliet P; Heymans S
    J Mol Cell Cardiol; 2011 Sep; 51(3):318-28. PubMed ID: 21624372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic Deletion of Galectin-3 Exacerbates Age-Related Myocardial Hypertrophy and Fibrosis in Mice.
    Fontana Estevez FS; Betazza MC; Miksztowicz V; Seropian IM; Silva MG; Penas F; Touceda V; Selser C; Villaverde A; Goren N; Cianciulli TF; Medina V; Morales C; Gironacci M; González GE
    Cell Physiol Biochem; 2022 Aug; 56(4):353-366. PubMed ID: 35959709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin.
    Yokoyama C; Aoyama T; Ido T; Kakino A; Shiraki T; Tanaka T; Nishigaki K; Hasegawa A; Fujita Y; Sawamura T; Minatoguchi S
    PLoS One; 2016; 11(5):e0154994. PubMed ID: 27195769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 deficiency ameliorates fibrosis and remodeling in dilated cardiomyopathy mice with enhanced Mst1 signaling.
    Nguyen MN; Ziemann M; Kiriazis H; Su Y; Thomas Z; Lu Q; Donner DG; Zhao WB; Rafehi H; Sadoshima J; McMullen JR; El-Osta A; Du XJ
    Am J Physiol Heart Circ Physiol; 2019 Jan; 316(1):H45-H60. PubMed ID: 30387702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracycline cardiotoxicity is exacerbated by global p38β genetic ablation in a sexually dimorphic manner but unaltered by cardiomyocyte-specific p38α loss.
    George SA; Kiss A; Trampel KA; Obaid SN; Tang L; Efimov IR; Efimova T
    Am J Physiol Heart Circ Physiol; 2023 Nov; 325(5):H983-H997. PubMed ID: 37624097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice.
    Ikeda Y; Aihara K; Akaike M; Sato T; Ishikawa K; Ise T; Yagi S; Iwase T; Ueda Y; Yoshida S; Azuma H; Walsh K; Tamaki T; Kato S; Matsumoto T
    Mol Endocrinol; 2010 Jul; 24(7):1338-48. PubMed ID: 20501642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adiponectin agonist ADP355 ameliorates doxorubicin-induced cardiotoxicity by decreasing cardiomyocyte apoptosis and oxidative stress.
    Zhao D; Xue C; Li J; Feng K; Zeng P; Chen Y; Duan Y; Zhang S; Li X; Han J; Yang X
    Biochem Biophys Res Commun; 2020 Dec; 533(3):304-312. PubMed ID: 32958254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension.
    González GE; Rhaleb NE; D'Ambrosio MA; Nakagawa P; Liao TD; Peterson EL; Leung P; Dai X; Janic B; Liu YH; Yang XP; Carretero OA
    Am J Physiol Heart Circ Physiol; 2016 Nov; 311(5):H1287-H1296. PubMed ID: 27496875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Senescence marker protein 30 has a cardio-protective role in doxorubicin-induced cardiac dysfunction.
    Miyata M; Suzuki S; Misaka T; Shishido T; Saitoh S; Ishigami A; Kubota I; Takeishi Y
    PLoS One; 2013; 8(12):e79093. PubMed ID: 24391705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirt6 protects cardiomyocytes against doxorubicin-induced cardiotoxicity by inhibiting P53/Fas-dependent cell death and augmenting endogenous antioxidant defense mechanisms.
    Wu S; Lan J; Li L; Wang X; Tong M; Fu L; Zhang Y; Xu J; Chen X; Chen H; Li R; Wu Y; Xin J; Yan X; Li H; Xue K; Li X; Zhuo C; Jiang W
    Cell Biol Toxicol; 2023 Feb; 39(1):237-258. PubMed ID: 34713381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX5A Alleviates Doxorubicin-Induced Cardiotoxicity by Suppressing Oxidative Stress, Mitochondrial Dysfunction and Cardiomyocyte Apoptosis.
    Zhang P; Lu H; Wu Y; Lu D; Li C; Yang X; Chen Z; Qian J; Ge J
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trastuzumab potentiates doxorubicin-induced cardiotoxicity via activating the NLRP3 inflammasome in vivo and in vitro.
    Wei S; Ma W; Yang Y; Sun T; Jiang C; Liu J; Zhang B; Li W
    Biochem Pharmacol; 2023 Aug; 214():115662. PubMed ID: 37331637
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Tejera-Muñoz A; Cortés M; Rodriguez-Rodriguez A; Tejedor-Santamaria L; Marchant V; Rayego-Mateos S; Gimeno-Longas MJ; Leask A; Nguyen TQ; Martín M; Tuñón J; Rodríguez I; Ruiz-Ortega M; Rodrigues-Díez RR
    Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasomal Degradation of TRAF2 Mediates Mitochondrial Dysfunction in Doxorubicin-Cardiomyopathy.
    Dhingra R; Rabinovich-Nikitin I; Rothman S; Guberman M; Gang H; Margulets V; Jassal DS; Alagarsamy KN; Dhingra S; Valenzuela Ripoll C; Billia F; Diwan A; Javaheri A; Kirshenbaum LA
    Circulation; 2022 Sep; 146(12):934-954. PubMed ID: 35983756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted expression of cyclin D2 ameliorates late stage anthracycline cardiotoxicity.
    Zhu W; Reuter S; Field LJ
    Cardiovasc Res; 2019 Apr; 115(5):960-965. PubMed ID: 30423020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.